



Attorney Docket No.: 6443.500-US

BEST AVAILABLE COPY

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hansen et al.

Serial No.: 10/699,338

Group Art Unit: To be assigned

Filed: October 31, 2003

Examiner: To be assigned

For: Chemical Uncouplers for the Treatment of Obesity

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (7)


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on **January 6, 2004**

Dolly Kapadia
(name of person mailing paper)

Dolly Kapadia
(signature of person mailing paper)



Attorney Docket No.: 6443.500-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hansen et al.

Application No.: 10/699,338

Group Art Unit: To be assigned

Filed: October 31, 2003

Examiner: To be assigned

For: Chemical Uncouplers for the Treatment of Obesity

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. U.S. Patent No. 4,673,691
2. WO 00/06143 A1
3. De Grey, European Journal of Biochemistry, Vol. 269, 1995 (2002)
FEBS 2002



BEST AVAILABLE COPY

4. Goto et al., Chem. Pharm. Bull., Vol. 44, No. 3, pages 547-551 (1996)
5. Miyoshi et al., Biochimica and Biophysica Acta, Vol. 891, pages 293-299 (1987)
6. Terada et al., Biochimica and Biophysica Acta, Vol. 936, pages 504-512 (1988)
7. Shimokawa et al., Drug Development Research, Vol. 51, pages 43-48 (2000)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed within three months of the filing date of a national application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Respectfully submitted,



Rosemarie R. Wilk-Orescan, Reg. No. 45,220
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Date: January 6, 2004

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE



JAN 15 2004

Sheet 1 of 1

FORM PTO-144
(Rev. 2-32)

U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6443.500-US

Serial No. 10/699,338

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant Hansen et al

Filing Date October 31, 2001

Group To be assigned

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	De Grey, European Journal of Biochemistry, Vol. 269, 1995 (2002) FEBS 2002
	Goto et al., Chem. Pharm. Bull., Vol. 44, No. 3, pages 547-551 (1996)
	Miyoshi et al., Biochimica et Biophysica Acta, Vol. 891, pages 293-299 (1987)
	Terada et al., Biochimica and Biophysica Acta, Vol. 936, pages 504-512 (1988)
	Shimokawa et al., Drug Development Research, Vol. 51, pages 43-48 (2000)

EXAMINER.

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.